Item 8.01 Other Events.

On January 20, 2022, Kura Oncology, Inc. (the "Company") reported that the U.S. Food and Drug Administration (the "FDA") has lifted the partial clinical hold on the KOMET-001 Phase 1b study of KO-539 in patients with relapsed or refractory acute myeloid leukemia ("AML"). The partial clinical hold was lifted following agreement with the FDA on the Company's mitigation strategy for differentiation syndrome, a known adverse event related to differentiating agents in the treatment of AML.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses